Skip to main content

Drug Safety

      The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…
      Day 3 Recap: ACR 2024
      LEVI-04 a novel neurotropin3-i showed:
      -significant analgesia across all measures
      -improvement in functional measures a
      1 month ago
      LEVI-04 a novel neurotropin3-i showed: -significant analgesia across all measures -improvement in functional measures and PGA for all doses in a Ph2 RCT - well tolerated Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future @RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU
      PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE

      Met primary endpoint (NNT~6 for BICLA) & numerical improve
      1 month ago
      PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb
      #MDA5 #dermatomyositis assoc #ILD

      May do better w
      #tofacitinib vs #CNI in 515 pts

      Too bad they didn’t do a pragmati
      1 month ago
      #MDA5 #dermatomyositis assoc #ILD May do better w #tofacitinib vs #CNI in 515 pts Too bad they didn’t do a pragmatic RCT as we do t know the reasons for prescribing each #Rx But impressive survival w #tofa #ACR24 @ACRheum @RheumNow abst1736 https://t.co/HLJknSYcNJ
      Lot said about #ACR24 ABST1697:
      MTX in newly diagnosed PMR, neg RCT
      Many have said no hope for MTX in PMR now

      Agree doe
      1 month ago
      Lot said about #ACR24 ABST1697: MTX in newly diagnosed PMR, neg RCT Many have said no hope for MTX in PMR now Agree doesn't bode well However, MTX may still have role in established PMR @drceowen & I have made that call a priori @TheLancetRheum https://t.co/ywCJc0zHzC @RheumNow https://t.co/JUXk2tDNyR
      It is NO LONGER a ACCEPTABLE
      To NOT consider
      #MMF or #Cyclo + another proven #Rx
      Added to
      #HCQ and #tapering /limiti
      1 month ago
      It is NO LONGER a ACCEPTABLE To NOT consider #MMF or #Cyclo + another proven #Rx Added to #HCQ and #tapering /limiting #glucocorticoids RCTs in #lupus #nephritis support this ? Is which to add #belimumab #CNI #volclosporin #obinutuzimab #ACR #ACRbest @RheumNow @ACRheum https://t.co/a7WMFfCyXl
      Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.2024 Updated ACR…
      This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with…
      ×